Clinical Trial Update: The Clostridioides Difficile Trial of REC-3964 [Phase 2]

View source ↗

Summary

A Phase 2 trial of REC-3964 for recurrent Clostridioides difficile infection has been terminated, with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Clostridioides Difficile Infection

Drugs mentioned

• REC-3964

Snippet

Sponsor: Recursion Pharmaceuticals Inc. | Conditions: Recurrent Clostridioides Difficile Infection | Phase 2 | Status: TERMINATED | Results posted: 2025-11-17